ReviewJournal of the National Cancer Institute2017
Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.
Review in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.Materials today. Bio · 2026Review
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- Lung Cancer Cell-intrinsic Asparagine Synthetase Potentiates Anti-Tumor Immunity via Modulating Immunogenicity and Facilitating Immune Remodeling in Metastatic Tumor-draining Lymph Nodes.International journal of biological sciences · 2025Article
- An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.Nature communications · 2024Article
- Immune characteristics associated with lymph node metastasis in early-stage NSCLC.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Intratumor injected gold molecular clusters for NIR-II imaging and cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications.Biomaterials research · 2024Review
- Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity.Science advances · 2023Article
- Micro-syringe chip-guided intratumoral administration of lipid nanoparticles for targeted anticancer therapy.Biomaterials research · 2023Article
- Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia.Journal of experimental & clinical cancer research : CR · 2023Article
- Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments.Cancers · 2023Review
- Theoretical premises of a "three in one" therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review.Translational cancer research · 2021Review
- Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?Frontiers in immunology · 2021Review
- Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer.JAMA network open · 2020Article
- Bronchoscopic intratumoural therapies for non-small cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Model-Based Nanoengineered Pharmacokinetics of Iron-Doped Copper Oxide for Nanomedical Applications.Angewandte Chemie (International ed. in English) · 2020Article
- Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.Nature nanotechnology · 2019Article
- Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".Journal of the National Cancer Institute · 2017Article
- Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern cancer immunotherapies represent a major shift in paradigm with respect to how we understand innate and adaptive responses to malignancy. Successful tumors co-opt normal immunosurveillance mechanisms by potent interactions between the tumor and local draining lymph nodes. Tumor cells mediate a complex and dynamic immunoediting procedure that results in increased vascular efflux into the draining lymphatics, an immunosuppressive microenvironment rich in regulatory T-lymphocytes, dysfunctional antigen presentation, and downregulation of normal effector lymphocyte responses. Our current approach to reversing this process for antitumor effect involves mainly systemic administration of immunotherapeutic agents, many of which have become standard of care in the management of a variety of cancers. Despite this, we are still learning how best to administer these drugs alone and in combination to maximize efficacy while minimizing adverse events. Increasing evidence suggests that comparable efficacy may be achieved by local administration of immunotherapies in the tumor or tumor-draining lymph nodes with substantially lower doses and better tolerability, even with combination therapy. Herein, we review the literature on intratumoral and intranodal immunotherapies in preclinical models and early-phase studies, with particular emphasis on approaches potentially suitable for translation to larger-scale clinical trials.
Indexed as
Identifiers
29546344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.